One month after receiving a green light to move its cell therapy treatment for improving the outcomes of hematopoietic stem cell transplants into a Phase III clinical trial, MolMed SpA. is launching an initial public offering in which it is seeking up to €71.8 million (US$105.8 million). (BioWorld International)

One month after receiving a green light to move its cell therapy treatment for improving the outcomes of hematopoietic stem cell transplants into a Phase III clinical trial, MolMed SpA. is launching an initial public offering in which it is seeking up to €71.8 million (US$105.8 million). (BioWorld International)